Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.81% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Dec 31, 2022
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001493152-23-007129General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
7.20% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
95.05% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-153.17% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
95.13% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.16% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- -182.79%
- Current
- 7.20%
- Delta
- 189.99%
- Previous
- 92.16%
- Current
- 95.05%
- Delta
- 2.89%
- Previous
- -175.15%
- Current
- -153.17%
- Delta
- 21.98%
- Previous
- 119.81%
- Current
- 95.13%
- Delta
- -24.68%
- Previous
- 32.92%
- Current
- 29.16%
- Delta
- -3.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LCTX Fundamental State →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CASH_GENERATION_INCREASED →Transitioned To · LCTX MARGIN_INCREASED →Transitioned To · LCTX PROFITABILITY_INCREASED →Transitioned To · LCTX R_AND_D_INTENSITY_DECREASED →Transitioned To · LCTX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.